

# Sequential ring-opening of *trans*-1,4-cyclohexadiene dioxide for an expedient modular approach to 6,7-disubstituted ( $\pm$ )-hexahydro-benzo[1,4]oxazin-3-ones

Matthias Scheunemann,<sup>a,\*</sup> Dietlind Sorger,<sup>b</sup> Elena Kouznetsova,<sup>c</sup> Osama Sabri,<sup>b</sup> Reinhard Schliebs,<sup>c</sup> Barbara Wenzel<sup>a</sup> and Jörg Steinbach<sup>a,†</sup>

<sup>a</sup>Institute of Interdisciplinary Isotope Research, Permoserstraße 15, 04318 Leipzig, Germany

<sup>b</sup>Department of Nuclear Medicine, University of Leipzig, Stephanstraße 11, 04103 Leipzig, Germany

<sup>c</sup>Paul Flechsig Institute for Brain Research, University of Leipzig, Jahnallee 59, 04109 Leipzig, Germany


Received 17 April 2007; revised 23 May 2007; accepted 30 May 2007

Available online 5 June 2007

**Abstract**—A modular approach to novel 6-amino-7-hydroxysubstituted hexahydro-benzo[1,4]oxazin-3-ones has been developed. The method involves a sequential ring-opening of *trans*-1,4-cyclohexadiene dioxide with amino nucleophiles. The resultant mono-epoxide from benzylamine was converted to a general electrophilic precursor, which enables the parallel treatment with amino nucleophiles to obtain a series of cyclohexane-fused morpholin-3-ones.

© 2007 Elsevier Ltd. All rights reserved.

The ring-cleavage of strained heterocyclic electrophiles has been evaluated as one of the few reliable conversions for the assembly of variable structures via heteroatom–carbon bonds in ‘click’-chemistry.<sup>1</sup> Surprisingly, symmetric diepoxides have scarcely been used for sequential opening with not identical heteroatom nucleophiles,<sup>2</sup> in contrast to concurrent diepoxide ring-opening applying a single nucleophile.<sup>1a</sup> Until now, only *trans*-cyclopenta-1,3-diene dioxide was regarded for an intermolecular reaction sequence with varying amines.<sup>3</sup> In the search for a new approach to variously substituted cyclohexane-fused morpholin-3-ones (**2a** and **2b**, Scheme 1), we attempted to take advantage of sequentially attacking the two electrophilic sites of *trans*-1,4-cyclohexadiene dioxide (**1**) by two different amines. The morpholin-3-one motif, found in only a few natural products,<sup>4</sup> is quested as valuable intermediate for numerous conversions.<sup>5</sup> By comparison, cyclohexane-fused morpholin-3-ones (hexahydro-benzo[1,4]oxazin-



Scheme 1.


3-ones) were also frequently processed in reactions such as ring-opening,<sup>6</sup> annulation,<sup>7</sup> or reduction.<sup>8</sup>

The latter scaffold resembles closely to the decahydro-naphthalene and decahydro-quinoline substructure. Both have been used as constituents of conformationally fixed analogues of vesamicol (Scheme 1, **4**), which is the parent structure of numerous ligands for the vesicular acetylcholine transporter (VACHT).<sup>9</sup> The VACHT is esteemed as a favourable target to detect pathological alterations of cholinergic terminals by PET (positron emission tomography).<sup>10</sup> Derivatives consisting of a

**Keywords:** Diepoxide; Ring-opening; Hexahydro-benzo[1,4]oxazin-3-ones; VACHT.

\* Corresponding author. Tel.: +49 0341 235 2636; fax: +49 0341 235 2731; e-mail: [scheunemann@iif-leipzig.de](mailto:scheunemann@iif-leipzig.de)

† Present address: Forschungszentrum Dresden, Institute of Radiopharmacy, PO Box 510119, 01314, Dresden, Germany.



Scheme 2.

bicyclic skeleton, such as **5**<sup>11</sup> and **6**,<sup>12</sup> have been communicated as highly potent VAcHT ligands. In the continuous search for new VAcHT ligands with improved binding profiles,<sup>13</sup> we were interested in structures such as **2a,b** and **3a,b** as rigid analogues of **4**. In this Letter, we describe the synthesis of different 6-amino-7-hydroxysubstituted hexahydro-benzo[1,4]oxazin-3-ones using the sequential ring-opening of *trans*-1,4-cyclohexadiene dioxide as a key step. The required diepoxide **1** was prepared from cyclohexa-1,4-diene by applying the well-tried combination of methyltrioxorhenium (MTO)/hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) with pyridine as additive.<sup>14</sup> An experiment for the partial cleavage of **1** at the outset of our study is depicted in Scheme 2.

The treatment of 4-phenyl-piperidine (**7a**) with a two-fold excess (200 mol %) of *trans*-1,4-cyclohexadiene dioxide (**1**) in EtOH at 90–95 °C for 16 h in a closed vessel led to the desired mono-epoxide **8a** in 75% yield and **9a**, which was isolated in 12% yield.<sup>15,16</sup> Further investigations towards product distribution and efficiency of conversions were carried out with a series of secondary amines (**7a–e**) and benzylamine (**7f**). The results are summarized in Table 1.

The application of 100 mol % **1** in relation to **7a** led to **8a** in 36% yield (Table 1, entry 2), which, in contrast to entry 1, clearly demonstrated the necessity to use an overstoichiometric amount of the diepoxide. As expected, a decrease of **1** to 50 mol % resulted in **9a** as the single product (Table 1, entry 3). In experiments of **1** with a couple of other secondary amines, it has been shown to be beneficial to raise the molar ratio from 2:1 to 5:1 (Table 1, entry 4 vs 6, 7 vs 8, 9 vs 10). Both selectivity and yield were positively affected by increasing the amount of **1** to 500 mol %. In addition, the reaction time sufficient for the total conversion of the amine was reduced to 1 h (Table 1, entries 6, 10 and 11). Somewhat longer reaction times were needed for the conversion of benzylic amines **7c** and **7f** (Table 1, entries 8 and 12). The bulk of unreacted *trans*-1,4-cyclohexadiene dioxide (**1**) could be readily recovered by applying a simple extraction procedure during work-up. It should be noted that all diols isolated (**9a–d**) were proven to result from a second nucleophilic cleavage on the 3-position in relation to the position of the primarily attacking nucleophile.<sup>17</sup> The appearance of four individual <sup>13</sup>C-signals for the cyclohexane moiety corresponds to a molecule with C<sub>2</sub>-symmetry.<sup>18</sup> This was expected and is in accor-

Table 1. Products from the reaction of **1** with amines **7a–f** (Scheme 2)<sup>a</sup>

| Entry | Reactants |                                  | Time (h) | Isolated products |                           |           |                           |
|-------|-----------|----------------------------------|----------|-------------------|---------------------------|-----------|---------------------------|
|       | Amine     | <b>1</b> <sup>b</sup><br>(mol %) |          | No.               | Yield <sup>c</sup><br>(%) | No.       | Yield <sup>c</sup><br>(%) |
| 1     | <b>7a</b> | 200                              | 16       | <b>8a</b>         | 75 (68)                   | <b>9a</b> | 12                        |
| 2     | <b>7a</b> | 100                              | 22       | <b>8a</b>         | 36                        | <b>9a</b> | 34                        |
| 3     | <b>7a</b> | 50                               | 72       | —                 | — <sup>d</sup>            | <b>9a</b> | 78                        |
| 4     | <b>7b</b> | 200                              | 13       | <b>8b</b>         | 70 (42)                   | <b>9b</b> | 15                        |
| 5     | <b>7b</b> | 300                              | 5        | <b>8b</b>         | 75 (43)                   | <b>9b</b> | 9                         |
| 6     | <b>7b</b> | 500                              | 1        | <b>8b</b>         | 83 (71)                   | <b>9b</b> | 5                         |
| 7     | <b>7c</b> | 200                              | 12       | <b>8c</b>         | 52 (15)                   | <b>9c</b> | 12                        |
| 8     | <b>7c</b> | 500                              | 1.5      | <b>8c</b>         | 76 (61)                   | <b>9c</b> | 5                         |
| 9     | <b>7d</b> | 200                              | 5        | <b>8d</b>         | 53 (32)                   | <b>9d</b> | 11                        |
| 10    | <b>7d</b> | 500                              | 1        | <b>8d</b>         | 79 (70)                   | <b>9d</b> | 4                         |
| 11    | <b>7e</b> | 500                              | 1        | <b>8e</b>         | 72                        | —         | <sup>d</sup>              |
| 12    | <b>7f</b> | 500                              | 2.5      | <b>8f</b>         | 60 (52)                   | —         | <sup>d</sup>              |

<sup>a</sup> Reaction conditions: **1** in EtOH [~1.25 M], entry 3: **1** in EtOH [~0.62 M], amine [**7a–f**, 0.2–2 equiv], stirring in a closed vessel at 95 °C; all products are racemic, the formulae represent *relative* configurations.

<sup>b</sup> Surplus of **1** was recovered in yields of 90–99%.<sup>15</sup>

<sup>c</sup> Overall yields of isolated products after chromatographic purification; yields in parenthesis refer to crystallized products, after removal of **1**; **8a–f**, **9a–d** are new compounds and were fully characterized.

<sup>d</sup> Compound **8a** was not observed; diols **9e** and **9f** were not isolated.

dance to the known *trans*-diaxial selectivity of nucleophilic cleavages on **1**.<sup>1a,18,19</sup>

Having in hands electrophilic 4-amino-7-oxa-bicyclo-[4.1.0]heptan-3-ols (**8a–f**), we turned our interest to the modular synthesis of non-symmetrical 4,6-di-amino cyclohexane-1,3-diols starting from **8a**.


As outlined in Table 2, the attack of **7f** or **7g** on **8a** led with high regio- and stereoselectivity to compounds **10b** and **10c** (Table 2, entries 2 and 3). However, crystalline products were obtained only in moderate yields. In comparison, smaller and more nucleophilic amines (**7h,i,k**),

Table 2. Amino-6-(4-phenyl-piperidin-1-yl)-cyclohexane-1,3-diols (**10a–e**) from the reaction of **8a** with amines<sup>a</sup>

| Entry | Amine   | Ratio<br><b>7/8a</b> | Time (h) | Product |                           |
|-------|---|----------------------|----------|---------|---------------------------|
|       |   |                      |          | No.     | Yield <sup>b</sup><br>(%) |
| 1     | NH <sub>3</sub>                                 | <b>7h</b>            | 65       | 10      | <b>10a</b> 99             |
| 2     | BnNH <sub>2</sub>                               | <b>7f</b>            | 6        | 16      | <b>10b</b> 54             |
| 3     | 4-FBnNH <sub>2</sub>                            | <b>7g</b>            | 4        | 8       | <b>10c</b> 72             |
| 4     | HOC <sub>2</sub> H <sub>4</sub> NH <sub>2</sub> | <b>7i</b>            | 10       | 10      | <b>10d</b> 96             |
| 5     | HOC <sub>2</sub> H <sub>4</sub> NHMe            | <b>7k</b>            | 4        | 13      | <b>10e</b> 85             |

<sup>a</sup> Reaction conditions: **8a** in EtOH [~1.0 M], amine [**7f–g**, **7i–k**, 4–10 equiv], stirring in a closed vessel at 95 °C; entry 1: **7h** [30% w/w in H<sub>2</sub>O, 65 equiv], stirring at 85–90 °C; all products are racemic, the formulae represent *relative* configurations.

<sup>b</sup> Yields of isolated products; **10a–e** are new compounds and were fully characterized.



Scheme 3.

which were applied in molar ratios of 4–10 (65 for ammonia, **7h**), led to the expected products from a *trans*-diaxial attack in excellent yields (Table 2, entries 1, 4 and 5).<sup>20</sup>

In a preliminary attempt to obtain 6,7-disubstituted hexahydro-benzo[1,4]oxazin-3-ones, the *N*-benzylamine derivative **10b** was needed and it was appropriately synthesized by a reductive benzylation of **10a** (Scheme 3). This procedure displayed an overall yield of 85% for three steps, which is in contrast to the only moderate yield of **10b** obtained in direct synthesis from **8a** and benzylamine (**7f**, Table 2, entry 2).

A standard sequence was applied to synthesize hexahydro-benzo[1,4]oxazin-3-ones **2a** and **2b** (Scheme 3). *N*-Chloroacetylation of **10a** and **10b** was carried out according to Schotten–Baumann conditions. For the ring closure of **11a** and **11b**, working in a solution of sodium *iso*-propanolate in *iso*-propanol (*i*-PrOH) has been found to yield **2a** and **2b** in 65% and 96%, respectively.

In order to achieve a superior access to **2b**, which might allow a parallel processing of a series of diverse amines, a general precursor **12** was conceived and prepared in two steps from **8f** (Scheme 3).

Epoxide **12** proved to be very useful as exemplified in a number of conversions with primary and secondary amines. The results are summarized in Table 3. In addition to experiments performed in *i*-PrOH at 95–100 °C, we also tested water as a reaction medium at 65–70 °C (Table 3, entries 2 and 7). Regarding reaction time and molar ratio of reactants, the most striking solvent effect was disclosed in the reaction with the bulky primary amine **7n**. Generally, reactions in water occurred faster (Table 3, entry 1 vs 2, entry 6 vs 7) and at a smaller amount of amine. However, the yields of **2b** and **2f** did not differ significantly from reactions proceeded in *i*-PrOH. Both products from the reaction of **7a** (Table 3, entries 1 and 2) were found to be identical with compound **2b** prepared via the aforementioned sequence starting from **10a** (Scheme 3). This outcome reempha-

Table 3. Formation of hexahydro-benzo[1,4]oxazin-3-ones (**2b–f**)<sup>a</sup>

| Entry | Amine                   | Ratio 7/12 | Time (h) | Solv. | Product          |                        |    |
|-------|-------------------------|------------|----------|-------|------------------|------------------------|----|
|       |                         |            |          |       | No.              | Yield <sup>b</sup> (%) |    |
| 1     | 4-Phenyl-piperidine     | <b>7a</b>  | 1.04     | 10    | <i>i</i> -PrOH   | <b>2b</b>              | 74 |
| 2     | 4-Phenyl-piperidine     | <b>7a</b>  | 1.00     | 2     | H <sub>2</sub> O | <b>2b</b>              | 77 |
| 3     | 4-Phenyl-piperazine     | <b>7b</b>  | 1.04     | 9     | <i>i</i> -PrOH   | <b>2c</b>              | 93 |
| 4     | Pyrrolidine             | <b>7l</b>  | 1.60     | 5     | <i>i</i> -PrOH   | <b>2d</b>              | 83 |
| 5     | Piperidine              | <b>7m</b>  | 1.60     | 7     | <i>i</i> -PrOH   | <b>2e</b>              | 76 |
| 6     | <i>tert</i> -Butylamine | <b>7n</b>  | 20.0     | 96    | <i>i</i> -PrOH   | <b>2f</b>              | 83 |
| 7     | <i>tert</i> -Butylamine | <b>7n</b>  | 2.00     | 15    | H <sub>2</sub> O | <b>2f</b>              | 75 |

<sup>a</sup> Reaction conditions: Entries 1, 3–6: **12** in *i*-PrOH [~1.25 M], amine [**7a,b,l–n**: 1.04–20 equiv], stirring in a closed vessel at 95–100 °C; Entries 2 and 7: **12** [1 equiv], H<sub>2</sub>O [~100 equiv], amine [**7a,n**: 1–2 equiv], stirring at 65–70 °C; all products are racemic, the formulae represent *relative* configurations.

<sup>b</sup> Yields of isolated crystallized products; **2b–f** are new compounds and were fully characterized.

sized the mode of regioselectivity of aminolytic cleavages on substituted epoxides, such as **8a** and **12**.

Finally, we performed the conversion of **2a** and **2b** to the novel octahydro-benzo[1,4]oxazines **3a** and **3b**, respectively (Scheme 3). The reductions were carried out using borane dimethylsulfide complex in refluxing tetrahydrofuran. Secondary amine **3a**<sup>21</sup> was also accessible via debenzoylation of **3b**. All new compounds were analyzed by <sup>1</sup>H, <sup>13</sup>C NMR spectroscopy and mass spectrometry (TOF-MS, electrospray) confirming the proposed structures.

In conclusion, we developed an efficient procedure to attain partial aminolyses of *trans*-1,4-cyclohexadiene dioxide (**1**) with a range of different amines leading to reactive mono-epoxides (**8a–f**). Starting from **8a** we have diastereoselectively synthesized novel octahydro-benzo[1,4]oxazines (**3a,b**) via four steps. A general precursor, **12**, was prepared from **8f** and utilized for a straight approach to a series of diverse hexahydro-benzo[1,4]oxazin-3-ones (**2b–f**). Further investigations towards the enantiomerically pure synthesis of hexahydro-benzo[1,4]oxazin-3-ones are now in progress and will be published in a forthcoming paper.

### Acknowledgement

This work was supported by the Saxonian Ministry of Science and Education, Biotechnologie-Förderung, SMWK-BEF, 7531.50-03-0361-01/6.

### References and notes

- (a) Kolb, H. C.; Finn, M. G.; Sharpless, K. B. *Angew. Chem., Int. Ed.* **2001**, *40*, 2004–2021; (b) Kolb, H. C.; Sharpless, K. B. *Drug Discovery Today* **2003**, *8*, 1128–1137.
- For recent examples, see: (a) Tok, J. B.-H.; Fenker, J. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 2987–2992; (b) Farkas, F.; Sequin, U.; Bur, D.; Zehnder, M. *Tetrahedron* **1992**, *48*, 103–110; (c) Jost, S.; Vanbellinghen, L.; Henderson, P.; Marchand-Brynaert, J. *Org. Prep. Proced. Int.* **1999**, *31*, 193–200.
- A preparation of one compound applying two different amines was described: Kozlov, N. S.; Yakubovich, L. S.; Zhavnerko, K. A.; Prischchenko, V. M. *J. Org. Chem. USSR* **1982**, *18*, 1842–1846.
- Ciminiello, P.; Dell'Aversano, C.; Fattorusso, E.; Forino, M.; Magno, S.; Santelia, F. U.; Moutsos, V. I.; Pitsinos, E. N.; Couladouros, E. A. *Tetrahedron* **2006**, *62*, 7738–7743.
- (a) Dobrev, A.; Nechev, L.; Ivanov, C.; Bon, M. *J. Chem. Res. Synops.* **1999**, 188–189; (b) Sandmann, G.; Mitchell, G. *J. Agric. Food Chem.* **2001**, *49*, 138–141; (c) Bouron, E.; Goussard, G.; Marchand, C.; Bonin, M.; Pannecoucke, X.; Quirion, J.-C.; Husson, H.-P. *Tetrahedron Lett.* **1999**, *40*, 7227–7230.
- Arndt, H.-D.; Ziemer, B.; Koert, U. *Org. Lett.* **2004**, *6*, 3269–3272.
- Bernáth, G.; Fülöp, F.; Argay, G.; Kálmán, A.; Sohár, P. *Tetrahedron Lett.* **1981**, *22*, 3797–3800.
- Matzanke, N.; Löwe, W.; Perachon, S.; Sokoloff, P.; Schwartz, J.-C.; Stark, H. *Eur. J. Med. Chem.* **1999**, *34*, 791–798.
- Rogers, G. A.; Parsons, S. M.; Anderson, D. C.; Nilsson, L. M.; Bahr, B. A.; Kornreich, W. D.; Kaufman, R.; Jacobs, R. S.; Kirtman, B. *J. Med. Chem.* **1989**, *32*, 1217–1230.
- Efange, S. M. N. *FASEB J.* **2000**, *14*, 2401–2413.
- Rogers, G. A.; Kornreich, W. D.; Hand, K.; Parsons, S. M. *Mol. Pharmacol.* **1993**, *44*, 633–641.
- Efange, S. M. N.; Khare, A. B.; Mach, R. H.; Parsons, S. M. *J. Med. Chem.* **1999**, *42*, 2862–2869.
- (a) Scheunemann, M.; Sorger, D.; Wenzel, B.; Heinitz, K.; Schliebs, R.; Klingner, M.; Sabri, O.; Steinbach, J. *Bioorg. Med. Chem.* **2004**, *12*, 1459–1465; (b) Wenzel, B.; Sorger, D.; Heinitz, K.; Scheunemann, M.; Schliebs, R.; Steinbach, J.; Sabri, O. *Eur. J. Med. Chem.* **2005**, *40*, 1197–1205.
- Rudolph, J.; Reddy, K. L.; Chiang, J. P.; Sharpless, K. B. *J. Am. Chem. Soc.* **1997**, *62*, 6189–6190.
- Preparation of (±)-**8a** via partial ring-opening of **1**: A mixture of **7a** (2.59 g, 16.05 mmol) and **1** (3.6 g, 32.1 mmol) in ethanol (20 mL) was stirred in a closed thick-walled glass flask for 16 h at 95 °C. After cooling, the crystalline precipitate was filtered off, washed with cold ethanol, and dried to give **8a** (2.98 g, 68%). After evaporation, the residue was treated with a mixture of citric acid (25%, 2.5 mL) and methyl *tert*-butyl ether (MTBE, 15 mL), and allowed to stir for 10 min. The organic layer was separated and the aqueous layer was extracted with MTBE (6 × 3 mL). The combined organic fractions were dried (Na<sub>2</sub>CO<sub>3</sub>), filtered, and concentrated to afford the bulk of unreacted **1** (1.69 g, 94% recovery) as off-white crystalline solid in pure form, which could be utilized again. The aqueous layer was made alkaline with 10% K<sub>2</sub>CO<sub>3</sub>. A sticky material precipitated, which was extracted with methylene chloride (CH<sub>2</sub>Cl<sub>2</sub>, 3 × 4 mL). The combined organic fractions were collected and concentrated. The residue was purified by flash column chromatography on silica gel 60 (CH<sub>2</sub>Cl<sub>2</sub>, MeOH, NH<sub>4</sub>OH [30% in H<sub>2</sub>O]; 10:1:0.1) to afford the remainder of **8a** (310 mg, 7%) and diol **9a** (417 mg, 12%).
- Analytical data for (±)-**8a** as selected compound: White solid; mp 152–154 °C (ethanol); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.60–1.72 (m, 2H), 1.79 (ddd, 1H, *J* = 12, 12, 4.8 Hz), 1.85–1.90 (m, 2H), 1.98 (dd, 1H, *J* = 14.8, 12 Hz), 2.10–2.18 (m, 1H), 2.25 (dt-like, 1H, *J* = 11.4, 2.4 Hz), 2.38–2.53 (m, 2H), 2.68–2.82 (m, 4H), 3.18–3.21 (m, 2H), 3.61 (dt-like, 1H, *J* = 10, 5.2 Hz), 3.98 (br s, 1H), 7.18–7.22 (m, 3H), 7.29–7.32 (m, 2H); <sup>13</sup>C NMR (100.567 MHz, CDCl<sub>3</sub>): δ<sub>C</sub> 20.87, 33.05, 33.70, 34.21, 42.72, 44.77, 51.43, 53.03, 53.33, 62.69, 65.36, 126.17, 126.72, 128.38, 145.92; MS (ESI) *m/z* 274.2 [(M+H)<sup>+</sup>]; Anal. Calcd for C<sub>17</sub>H<sub>23</sub>NO<sub>2</sub>: C, 74.69; H, 8.48; N, 5.12. Found: C, 74.99; H, 8.80; N, 5.16.
- Analytical data for (±)-**9a**: White solid; mp 148.5–150 °C (ethyl acetate/*n*-hexane, 1:4); <sup>1</sup>H NMR (200.140 MHz, CDCl<sub>3</sub>): δ<sub>H</sub> 1.59–1.94 (m, 10H, 5-H<sub>2</sub>, Pip: 2 × 3'-H<sub>2</sub>, 2 × 5'-H<sub>2</sub>), 2.02 (t-like, *J* = 5.9 Hz, 2H, 2-H<sub>2</sub>), 2.06–2.20 (m, 2H, Pip: 2 × 2'-H<sub>b</sub>), 2.31–2.64 (m, 6H, 4-H, 6-H, Pip: 2 × 4'-H, 2 × 6'-H<sub>b</sub>), 2.78 (br, 2H, 2 × OH), 2.90–3.02, 3.05–3.15 (2m, 4H, Pip: 2 × 4'-H, Pip: 2 × 2'-H<sub>a</sub>, 2 × 6'-H<sub>a</sub>), 4.08 (dt-like, *J* = 5.9, 5.9 Hz, 2H, 1-H, 3-H), 7.15–7.35 (m, 10H, ArH). <sup>13</sup>C NMR (50.325 MHz, CDCl<sub>3</sub>): δ<sub>C</sub> 18.84 (1C, 5-C), 33.96 (2C, Pip: 2 × 3'-C), 34.18 (2C, Pip: 2 × 5'-C), 35.38 (1C, 2-C), 43.04 (2C, Pip: 2 × 4'-C), 47.90 (2C, Pip: 2 × 2'-C), 52.97 (2C, Pip: 2 × 6'-C), 64.54 (2C, 4-C, 6-C), 65.94 (2C, 1-C, 3-C), 126.28 (2C<sub>Ar</sub>, 2 × 4''-C), 126.94 (4C<sub>Ar</sub>), 128.54 (4C<sub>Ar</sub>), 146.43 (2C<sub>Ar</sub>, 2 × 1''-C); MS (ESI)

- $m/z$  435.3 [(M+H)<sup>+</sup>]; Anal. Calcd for C<sub>28</sub>H<sub>38</sub>N<sub>2</sub>O<sub>2</sub>: C, 77.38; H, 8.81; N, 6.45. Found: C, 77.00; H, 8.82; N, 6.47.
18. In contrast, an attack on position 4 would lead to a molecule with C<sub>i</sub>-symmetry, which would exhibit three signals for the cyclohexyl carbons. A descriptive example has been published: Ironmonger, A.; Stockley, P.; Nelson, A. *Org. Biomol. Chem.* **2005**, *3*, 2350–2353.
19. (a) Craig, T. W.; Harvey, G. R.; Berchtold, G. A. *J. Org. Chem.* **1967**, *32*, 3743–3749; (b) Gruber-Khadjawi, M.; Hönig, H.; Illaszewicz, C. *Tetrahedron: Asymmetry* **1996**, *7*, 807–814; (c) Barz, M.; Glas, H.; Thiel, W. R. *Synthesis* **1998**, 1269–1273.
20. Fürst, A.; Plattner, P. A. *Helv. Chim. Acta* **1949**, *32*, 275–283.
21. *Selected physical data for compound (±)-3a*: White solid; mp 218.5–219.5 °C (CHCl<sub>3</sub>/methyl *tert*-butylether); <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>/CDCl<sub>3</sub>): δ 1.50–2.10 (m, 10H), 2.20 (br s, 1H), 2.28–2.48 (m, 2H), 2.59–2.80 (m, 2H), 2.87–3.13 (m, 3H), 3.28–3.42 (m, 2H), 3.50–3.56 (m, 1H), 3.73–3.79 (m, 1H), 4.14 (br s, 1H), 7.08–7.25 (m, 5H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 27.6, 33.3, 33.68, 33.74, 42.7, 46.6, 50.2, 52.3, 54.6, 64.2, 66.9, 68.4, 77.6, 125.9, 126.7, 128.2, 146.4; MS (ESI)  $m/z$  317.2 [(M+H)<sup>+</sup>].